logo
Plus   Neg
Share
Email

Khiron Life Sciences Fills First Prescriptions For Medical Cannabis In Peru

Khiron Life Sciences Corp. said Thursday it has filled the first prescriptions for medical cannabis to patients in Peru, and also surpassed the milestone of 3,000 medical cannabis prescriptions in Colombia.

Khiron noted that it is the first company to sell and fill full-spectrum high CBD or cannabidiol medical cannabis prescriptions through private pharmacies in Peru. This comes following authorization from DIGEMID, Peru's drug regulatory authority.

The Canada-based cannabis company has now expanded sales of its medical cannabis to a second jurisdiction in Latin America, following established sales in Colombia, where it has filled more than 3,000 prescriptions to date.

The company said it began sales in Peru with full spectrum High CBD supplied by Khiron Colombia and distributed to patients under its previously announced deal with Peruvian pharmacy chain Farmacia Universal S.A.C.

Farmacia operates ten locations in Lima and has a dominant position in the pharmaceutical preparations sector in Peru.

"After completing successfully all export, import and distribution requirements to bring our approved high CBD medical cannabis products into Peru, we are now very proud to begin sales and give patients greater access to medical cannabis therapies in order to improve significantly their quality of life," said Luis Marquez, Khiron Peru Country Manager.

CBD is a naturally occurring cannabinoid constituent of cannabis. It is a chemical in the marijuana plant often used for medicinal purposes, and does not have the intoxicating effects like those caused by tetrahydrocannabinol or THC.

Khiron Peru is a GSP certified, registered pharmaceutical establishment.

The company noted that Farmacia Universal has all required permits and licenses, including Good Manufacturing Practices or GMP certification, to prepare magistral preparations with medical cannabis and also distribute final products to patients through pharmacies under its agreement with Khiron.

Further, Khiron said that DIGEMID has approved quotas for its high THC medical cannabis product in Peru, with first patient prescriptions anticipated to be filled in the fourth quarter of 2020.

With a population of 32 million, Peru's medical cannabis market is expected to be one of the largest in Latin America.

For comments and feedback contact: editorial@rttnews.com

Health News

Follow RTT